ARTICLE | Clinical News

Sublingual grass pollen allergen: Phase I/II started

February 20, 2006 8:00 AM UTC

AGY started a double-blind, placebo-controlled, German Phase I/II MPL103 trial in 80 patients. The trial involves 4 cohorts of 20 patients each, 16 of which will receive the vaccine and 4 placebo. The...